| US 7,575,742 B2 | ||
| Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist | ||
| Roland Martin, Bethesda, Md. (US); Henry McFarland, Gaithersburg, Md. (US); Bibiana Bielekova, Kensington, Md. (US); and Thomas Waldmann, Silver Spring, Md. (US) | ||
| Assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, D.C. (US) | ||
| Appl. No. 10/519,311 PCT Filed Nov. 27, 2002, PCT No. PCT/US02/38290 § 371(c)(1), (2), (4) Date Dec. 22, 2004, PCT Pub. No. WO2004/002500, PCT Pub. Date Jan. 08, 2004. |
||
| Claims priority of provisional application 60/393021, filed on Jun. 28, 2002. | ||
| Prior Publication US 2005/0249704 A1, Nov. 10, 2005 | ||
| Int. Cl. A61K 38/21 (2006.01); A61K 39/395 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01) | ||
| U.S. Cl. 424—85.4 [424/143.1; 530/351; 530/388.22] | 22 Claims |
| 1. A method of treating a subject that has multiple sclerosis comprising:
administering to the subject that has multiple sclerosis a therapeutically effective amount of interferon-beta and a therapeutically
effective amount of an antibody that specifically binds the interleukin 2 receptor,
wherein the antibody that specifically binds the interleukin 2 receptor is administered every other week for two weeks and
then monthly; once a week; every other week; or once a month,
and wherein the subject has been treated previously with interferon-beta alone and has failed to respond to treatment with
interferon-beta alone,
thereby treating the subject.
|